Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 436.98
GNMSF's Cash to Debt is ranked higher than
75% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. GNMSF: 436.98 )
GNMSF' s 10-Year Cash to Debt Range
Min: 8.52   Max: No Debt
Current: 436.98

Equity to Asset 0.29
GNMSF's Equity to Asset is ranked higher than
53% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GNMSF: 0.29 )
GNMSF' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.62
Current: 0.29

0.21
0.62
F-Score: 4
Z-Score: 1.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -24.08
GNMSF's Operating margin (%) is ranked higher than
76% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. GNMSF: -24.08 )
GNMSF' s 10-Year Operating margin (%) Range
Min: -434.42   Max: 10760.13
Current: -24.08

-434.42
10760.13
Net-margin (%) -100.51
GNMSF's Net-margin (%) is ranked higher than
67% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. GNMSF: -100.51 )
GNMSF' s 10-Year Net-margin (%) Range
Min: -10124.65   Max: -55.23
Current: -100.51

-10124.65
-55.23
ROE (%) -127.12
GNMSF's ROE (%) is ranked higher than
53% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. GNMSF: -127.12 )
GNMSF' s 10-Year ROE (%) Range
Min: -127.12   Max: -13.3
Current: -127.12

-127.12
-13.3
ROA (%) -28.77
GNMSF's ROA (%) is ranked higher than
67% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. GNMSF: -28.77 )
GNMSF' s 10-Year ROA (%) Range
Min: -45.5   Max: -9.68
Current: -28.77

-45.5
-9.68
ROC (Joel Greenblatt) (%) -27.19
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. GNMSF: -27.19 )
GNMSF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -58.63   Max: 58.06
Current: -27.19

-58.63
58.06
Revenue Growth (%) -6.90
GNMSF's Revenue Growth (%) is ranked higher than
69% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. GNMSF: -6.90 )
GNMSF' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 331.5
Current: -6.9

0
331.5
EBITDA Growth (%) 13.70
GNMSF's EBITDA Growth (%) is ranked higher than
90% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. GNMSF: 13.70 )
GNMSF' s 10-Year EBITDA Growth (%) Range
Min: -65.7   Max: 115.5
Current: 13.7

-65.7
115.5
EPS Growth (%) -32.20
GNMSF's EPS Growth (%) is ranked higher than
61% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. GNMSF: -32.20 )
GNMSF' s 10-Year EPS Growth (%) Range
Min: -36   Max: 13.3
Current: -32.2

-36
13.3
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMSF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.90
GNMSF's P/B is ranked lower than
72% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. GNMSF: 19.90 )
GNMSF' s 10-Year P/B Range
Min: 1.63   Max: 24.95
Current: 19.9

1.63
24.95
P/S 15.55
GNMSF's P/S is ranked lower than
54% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. GNMSF: 15.55 )
GNMSF' s 10-Year P/S Range
Min: 3.08   Max: 42.95
Current: 15.55

3.08
42.95
EV-to-EBIT 1000.00
GNMSF's EV-to-EBIT is ranked lower than
87% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. GNMSF: 1000.00 )
GNMSF' s 10-Year EV-to-EBIT Range
Min: 1057.4   Max: 1571
Current: 1000

1057.4
1571

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.20
GNMSF's Price/Tangible Book is ranked lower than
82% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. GNMSF: 21.20 )
GNMSF' s 10-Year Price/Tangible Book Range
Min: 1.62   Max: 22.6
Current: 21.2

1.62
22.6
Price/Median PS Value 2.40
GNMSF's Price/Median PS Value is ranked lower than
61% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GNMSF: 2.40 )
GNMSF' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 5.22
Current: 2.4

0.5
5.22
Earnings Yield (Greenblatt) 0.10
GNMSF's Earnings Yield (Greenblatt) is ranked lower than
78% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GNMSF: 0.10 )
GNMSF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.1
Current: 0.1

Forward Rate of Return (Yacktman) -4.70
GNMSF's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. GNMSF: -4.70 )
GNMSF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.6   Max: -4.5
Current: -4.7

-6.6
-4.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GEN.Denmark
Genmab A/S is a biotechnology company that utilizes antibody products. The company's treatments focus on cancer and other serious illnesses. The company has a pipeline of drugs in various stages of development and approval. The company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The company has a myriad of other products in development, pending completion and approval. The company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.
» More Articles for OTCPK:GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide